2. Search Result
Search Result
Results for "

Aβ1-42 peptides

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

15

Peptides

1

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-113283
    Homogentisic acid

    		Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin Neurological Disease Metabolic Disease Cancer
    Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
    Homogentisic acid
  • HY-P5096
    FITC-β-Ala-Amyloid β-Protein (1-42)

    		Amyloid-β Neurological Disease
    FITC-β-Ala-Amyloid β-Protein (1-42) is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .
    FITC-β-Ala-Amyloid β-Protein (1-42)
  • HY-P3908
    FITC-β-Ala-Amyloid β-Protein (1-42) ammonium
    1 Publications Verification

    		 Amyloid-β Neurological Disease
    FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .
    FITC-β-Ala-Amyloid β-Protein (1-42) ammonium
  • HY-P3688A
    β-Amyloid (1-38) TFA

    Aβ (1-38) TFA; Aβ38 TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
    β-Amyloid (1-38) TFA
  • HY-P5905
    Citrullinated amyloid-β (1-42) peptide (human)

    Citrullinated Aβ (1-42); Citrullinated Aβ42

    		 Amyloid-β Neurological Disease
    Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .
    Citrullinated amyloid-β (1-42) peptide (human)
  • HY-P5156
    BDS-I

    		Potassium Channel Neurological Disease
    BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death .
    BDS-I
  • HY-P3688
    β-Amyloid (1-38)

    Aβ (1-38); Aβ38

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
    β-Amyloid (1-38)
  • HY-P4886A
    Amyloid β-Protein (3-42) TFA

    		Amyloid-β Neurological Disease
    Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).
    Amyloid β-Protein (3-42) TFA
  • HY-P4886
    Amyloid β-Protein (3-42)

    		Amyloid-β Neurological Disease
    Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .
    Amyloid β-Protein (3-42)
  • HY-P1051
    β-Amyloid (12-28)

    Amyloid β-Protein (12-28)

    		 Amyloid-β Neurological Disease
    β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .
    β-Amyloid (12-28)
  • HY-P4391
    (Asp37)-Amyloid β-Protein (1-42)

    		Amyloid-β Neurological Disease
    (Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide .
    (Asp37)-Amyloid β-Protein (1-42)
  • HY-P11047
    QSH peptide

    		Amyloid-β Neurological Disease
    QSH peptide is a peptide that specifically binds to Aβ1-42 and is used in the synthesis of siRNA delivery complexes. QSH peptide can be used in Alzheimer's disease (AD) research .
    QSH peptide
  • HY-P1051A
    β-Amyloid (12-28) TFA

    Amyloid β-Protein (12-28) TFA; Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .
    β-Amyloid (12-28) TFA
  • HY-162339
    BChE-IN-30

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC50: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .
    BChE-IN-30
  • HY-P10630
    Pep63

    		Amyloid-β Neurological Disease
    Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research .
    Pep63
  • HY-P10823
    RI-OR2

    		Amyloid-β Neurological Disease
    RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent Kd of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension .
    RI-OR2
  • HY-N1876
    Aromadendrane-4β,10α-diol

    		Others Neurological Disease
    Aromadendrane-4β,10α-diol is a sesquiterpene alcohol. Aromadendrane-4β,10α-diol significantly ameliorates the Aβ1-42 peptide-induced memory impairment. Aromadendrane-4β,10α-diol can be used for Alzheimer's disease (AD) research .
    Aromadendrane-4β,10α-diol
  • HY-P5370
    Scrambled β-amyloid (1-40)

    		Amyloid-β Others
    Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)
    Scrambled β-amyloid (1-40)
  • HY-133184
    Aminogenistein

    		Src γ-secretase Neurological Disease
    Aminogenistein is a p56 lck inhibitor with a 1.2 μM IC50. Aminogenistein inhibits production of Aβ1-40 and Aβ1-42 peptides. Aminogenistein induces accumulation of APP-CTFα and APP-CTFβ, indicating γ-secretase cleavage inhibition. Aminogenistein can be used for the research of alzheimer's disease .
    Aminogenistein
  • HY-P991534
    PF-04382923

    		Amyloid-β Neurological Disease
    PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
    PF-04382923
  • HY-182328
    BTA-EG6

    		Amyloid-β Neurological Disease
    BTA-EG6 is a brain-penetrant aggregated amyloid-β (Aβ) peptide binder with a Kd of 290 nM for Aβ1-42. BTA-EG6 binds to aggregated Aβ and forms protein-resistive coatings that block interactions between Aβ and catalase. BTA-EG6 protects neuroblastoma cells from Aβ-induced toxicity and oxidative stress, and inhibits Aβ-induced increases in cellular hydrogen peroxide (H2O2) levels. BTA-EG6 can be used for the research of alzheimer’s disease (AD) .
    BTA-EG6

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: